Medtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year ...

Medtronic released positive two-year trial Evolut TAVR results that demonstrated superior valve performance in small aortic ...

Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...

Medtronic plc released positive results from a two-year trial of Evolut TAVR that demonstrated superior valve performance in patients with small aortic annuli. The SMall Annuli Randomized To Evolut or ...

Per the latest update, the Evolut FX+ TAVR system is seeing strong uptake in the United States, with international expansion progressing well. With favorable trial results, Medtronic’s ...

Additional results demonstrated that Evolut TAVR showed the following relative ... which is part of the Cardiovascular Portfolio at Medtronic. "At two years, we continue to see superior valve ...

(RTTNews) - Medtronic plc (MDT ... as measured by bioprosthetic valve dysfunction (BVD) at two years for Evolut TAVR compared to SAPIEN. The SMART two-year data demonstrated that Evolut TAVR ...

"The two-year results highlight the continued superior performance of the Evolut TAVR valve in these patients. While we would not yet expect to see a significant difference in the composite ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMa ...

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...